Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 23.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 325,564 shares of the company's stock after selling 97,475 shares during the period. Wellington Management Group LLP owned approximately 0.70% of Omnicell worth $14,494,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in OMCL. KBC Group NV raised its holdings in shares of Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after purchasing an additional 778 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after buying an additional 699,925 shares during the last quarter. Empowered Funds LLC purchased a new stake in Omnicell during the fourth quarter valued at approximately $388,000. Shaker Investments LLC OH purchased a new stake in Omnicell during the fourth quarter valued at approximately $550,000. Finally, Van ECK Associates Corp increased its holdings in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMCL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Bank of America raised their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company reiterated an "overweight" rating and set a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Finally, Piper Sandler restated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Stock Performance

Shares of OMCL stock traded down $0.42 during trading hours on Thursday, hitting $30.87. The company's stock had a trading volume of 427,810 shares, compared to its average volume of 571,216. The company has a 50 day moving average of $30.17 and a 200 day moving average of $37.76. The stock has a market cap of $1.45 billion, a PE ratio of 114.34, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The business's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.